- Trial phase
- Filed/PDUFA (NDA under priority review)
- Time to market
- PDUFA target action date is December 27, 2026. If approved, a U.S. launch could follow in early 2027.
- Why 8/10
- The next hard, dated catalyst is the FDA PDUFA target action date of December 27, 2026, roughly six weeks from today, for the relutrigine NDA in SCN2A and SCN8A DEEs. This is a binary regulatory decision on a lead asset at a company that also has a second NDA (ulixacaltamide) under review, so the impact score reflects a major value driver with a near-term binary but not a single-asset make-or-break.
The next binary catalyst is the PDUFA decision on December 27, 2026, roughly six weeks away. Approval would likely drive a significant re-rating given no approved therapies exist for SCN2A/SCN8A DEEs, while a CRL would pressure the stock. Also watch for EMERALD study topline results in broad DEEs (Q4 2026), which could expand the addressable market.
Price Chart
Executive Summary
Relutrigine (PRAX-562) is Praxis Precision Medicines' lead epilepsy asset, a sodium channel functional state modulator targeting SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs), severe genetic childhood epilepsies with no approved therapies. The FDA accepted the NDA with priority review, granted Breakthrough Therapy Designation, and set a PDUFA target action date of December 27, 2026 (extended from September). The Phase 2 EMBOLD study was stopped early for efficacy, and positive results supported the submission. Praxis also has a second NDA (ulixacaltamide for essential tremor, PDUFA January 29, 2027) under review, and expects topline data from the EMERALD broad-DEE study in Q4 2026. The stock trades around $323 with a strong buy analyst consensus and a mean price target of ~$662, implying roughly 104% upside.
How It Works
Relutrigine is a sodium channel functional state modulator. In simple terms, it works by adjusting the activity of sodium channels on brain cells (neurons). In certain genetic forms of severe childhood epilepsy (SCN2A and SCN8A DEEs), mutations cause these sodium channels to malfunction, leading to excessive electrical activity and seizures. Relutrigine is designed to selectively correct that dysfunction by stabilizing the channel in its resting state, reducing runaway neuronal firing without broadly suppressing brain activity.
Trial Status
The pivotal Phase 2 EMBOLD study in SCN2A and SCN8A DEEs was stopped early for efficacy by the Data Monitoring Committee in December 2025. Positive topline results were announced, and the data served as the basis for the NDA submission. The FDA accepted the NDA with priority review in March 2026. An additional study, EMERALD, evaluating relutrigine in a broader DEE population, is ongoing with topline results expected in Q4 2026.
The Two-Sided Case
Upcoming Catalysts
- PDUFA target action date: December 27, 2026 (FDA decision on approval)
- EMERALD study topline results in broad DEEs: expected Q4 2026
- Potential label expansion into Dravet syndrome (Rare Pediatric Disease Designation already granted)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Praxis Precision Medicines, Inc. 8-K PRAX ·Originating report